Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Corporate Update (April 2020)
15 slides from Aim Immunotech's corporate update, Apr 16, 2020
Slide 1: Ampligen Overview: COVID-19 and Cancer
S AIM ImmunoTech Ampligen Overview COVID-19 and Cancer April 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: The COVID-19 Global Pandemic
The COVID-19 Global Pandemic We heard the first bits of information in December 2019 — a few stories of people coming down with a flu-like illness. What started off small quickly became too big to contain. SARS-CoV-2 — the virus that causes the disease COVID-19 — spread to other countries around the
Slide 4: Why Look to Ampligen for Help?
Why Look to Ampligen for Help? Following the SARS-CoV-1 outbreak in 2002-03, Ampligen exhibited excellent antiviral properties and protective survival effect in NIH-contracted studies of SARS-infected mice, which is almost identical to SARS-CoV-2. * The Barnard 2006 study (https://journals.sagepub.c
Slide 5: Ampligen has Potential as Prophylaxis and Early-onset Therapeutic
Ampligen has Potential as... ..a Prophylaxis for first responders ..an Early-onset Therapeutic for and other medical professionals to people who have been exposed to essentially armor themselves the coronavirus so that they can against the virus before treating stop the disease before serious new an
Slide 6: Progress in Initiating Clinical Trials to Study Ampligen's Activity
Progress in Initiating Clinical Trials to Study Ampligen’s Activity as a Potential Prophylactic and Early-Onset Therapeutic Against SARS-CoV-2 e Protocols are being developed to study Ampligen for several COVID-19 indications (prophylaxis and early-onset). e The protocol designs of two trials are un
Slide 7: AIM's Ongoing COVID-19 Efforts
AIM’s Ongoing COVID-19 Efforts e In January, when AIM learned of the new coronavirus epidemic, the company immediately began analyzing numerous research projects and previous tests related to Ampligen and the SARS-CoV-1 epidemic. Subsequently, AIM filed provisional patent applications for Ampligen a
Slide 8: Ampligen is a Broad-Spectrum Antiviral
Ampligen is a Broad-Spectrum Antiviral e Ampligen has demonstrated antiviral activity against a broad spectrum of viruses, including Herpes viruses, Alphaviruses, Coronaviruses and Filoviruses. e Ampligen has shown a survival benefit in Alphaviruses, Coronaviruses, Filoviruses and Paramyxoviruses in
Slide 9: Potential Advantages of Intranasal Use of Ampligen as a Vaccine Enhancer
Potential Advantages of Intranasal Use of Ampligen as a Vaccine Enhancer e Studies in mice and humans suggest that intranasal immunizations with Ampligen combined with trivalent seasonal influenza vaccine induce mucosal IgA and serum IgG antibodies, which could potentially protect humans from hetero
Slide 10: Ampligen and Immuno-Oncology
Ampligen and Immuno-Oncology Multiple Ampligen clinical trials are underway or preparing to be underway at university cancer centers testing whether tumor microenvironments can be reprogrammed to increase the effectiveness of cancer immunotherapy, including checkpoint inhibitors: ° Advanced Recurren
Slide 11: Ampligen and Immuno-Oncology
Ampligen and Immuno-Oncology Multiple Ampligen clinical trials are underway or preparing to be underway at university cancer centers testing whether tumor microenvironments can be reprogrammed to increase the effectiveness of cancer immunotherapy, including checkpoint inhibitors: ° Early-Stage Prost
Slide 12: Ampligen and Immuno-Oncology
Ampligen and Immuno-Oncology Additional Ampligen clinical trials are planned for initiation in 2020, subject to funding: * Stage 4 Urothelial, Melanoma and Renal Cell Carcinoma — Phase 2 study of advanced urothelial (bladder), melanoma and renal cell carcinoma, resistant to checkpoint blockade, that
Slide 13: Well-funded Interest in the Potential of Ampligen in Immuno-oncology
Well-funded Interest in the Potential of Ampligen in Immuno-oncology © The National Cancer Institute recently issued an award of $14.54 million to Roswell Park Comprehensive Cancer Center to test chemokine modulation incorporating Ampligen as an immuno-modulator as part of a strategy to turn ‘cold'
Slide 14: Ampligen has an Excellent Safety Profile
Ampligen has an Excellent Safety Profile * Well-developed safety profile based on more than 100,000 IV doses administered to humans. * Authorized in the U.S. by the FDA for use in numerous ongoing clinical trials. * Approved in Argentina for severe CFS. * Generally well tolerated in a number of FDA-
Slide 15: Fully Diluted Share Structure as of 3/31/20
in as of 3/31/20 Outstanding shares of common stock beneficially owned by Officers and Directors Common Shares Outstanding (including Officers and Directors) Series B Convertible Preferred (converts 5,000:1) Warrants Stock Options Total # of Shares 384,672 27,626,077 296,454 Common Equivalent 384,67